GermanyGermany

Cancer immunotherapeutics specialist immatics raises EUR54m

23.09.2010

Tuebingen – Private German immunotherapy specialist immatics biotechnologies GmbH has raised EUR53.8 million in a Series C financing round With new funds that the company will use to push its lead cancer vaccine IMA901 into a pivotal Phase III study in advanced renal cell carcinoma (RCC). IMA901 is designed to induce a polyclonal antibody response by 10 different so-called tumour-associated peptides (TUMAPs) that are frequently found to be over-expressed in a large subgroup of patients with renal cell carcinoma. The company said it expects to have first results from the trial (with overall survival as primary endpoint) at the end of 2013. Immatics, which was spun-off from Tuebingen University, also said it will advance its Phase II colorectal cancer vaccine IMA910 and its preclinical project IMA950 in patients with glioblastoma. The financing round was supported by both existing and new investors. Approximately half of the funds came from dievini Hopp Biotech holding, Wellington Partners and other existing shareholders, the other half coming from new investors MIG-advised funds and AT Impf GmbH.

GermanyGermany

16.07.2010

Hamburg/Göttingen - Hamburg-based drug screening specialist Evotec AG has entered into a definitive agreement with a group of shareholders from diabetes and obesity drug-developer DeveloGen AG to acquire a majority shareholding...

GermanyGermany

12.07.2010

Berlin – Germany is to invest EUR200 million over the coming 15 years to develop the next generation of biotechnology processes. “The full potential of biotechnology isn’t yet fully exploited”, said BMBF State Secretary Helge...

GermanyGermany

11.07.2010

Personalised medicine is all about treating an individual based on the specifics of his or her disease. However, both current EMA or FDA regulations and present clinical practice are stochastic, and thereby fundamentally in...

GermanyGermany

11.07.2010

Leuna – Peak oil prices and depleted fossil resources have dragged biomass into the limelight in the chemical industry. In Germany, pioneering work to use wood waste to produce bioplastics, platform chemicals or energy in a...

GermanyGermany

10.07.2010

Heidelberg – Practically overnight, a deal with Life Technologies has made the German Cancer Research Center (DKFZ) in Heidelberg one of Europe’s largest centres for next-generation sequencing. At the end of June, the researchers...

GermanyGermany

09.07.2010

Göttingen – A drug that regulates release of kidney hormones may help against the symptoms of jet-lag or shift work. In mid-June, Dr. Silke Kiessling and colleagues from the Max Planck Institute for Biophysical Chemistry in...

GermanyGermany

08.07.2010

Hamburg – To survive in man, the malaria parasite Plasmodium falciparum needs to enter the red blood cells for reproduction. Researchers from the Bernhard ­Nocht Institute for Tropical Medicine in Hamburg have now identified the...

GermanyGermany

08.07.2010

Limburgerhof/ St. Louis - To improve crop yield, US and European agrobiotech giants Monsanto and BASF will expand their development and commercialisation alliance aimed at developing higher- yielding and stress-tolerant crops. In...

GermanyGermany

05.07.2010

Martinsried – German antibody specialist MorphoSys AG has signed a worldwide exclusive licensing and collaboration agreement for the humanised Anti-CD19 monoclonal antibody XmAb5574 from US-based Xencor Inc as a potential...

GermanyGermany

02.07.2010

Frankfurt/Stanford – Most types of deafness arise from loss of parts the 15,000 hair cells of the inner ear. A US-German research team headed by Prof. Stefan Heller has, for the first time, succeeded in regenerating hair...

Displaying results 91 to 100 out of 454

< Previous 91-100 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-germany/browse/9/article/cancer-immunotherapeutics-specialist-immatics-raises-eur54-million.html

Events

All Events

Stock list

All quotes

TOP

  • NOVACYT (F)4.98 EUR5.96%
  • STALLERGENES (F)53.50 EUR4.37%
  • MORPHOSYS (D)72.25 EUR3.96%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • OREXO (S)137.00 SEK-5.35%

TOP

  • WILEX (D)3.10 EUR307.9%
  • SANTHERA (CH)67.95 CHF88.7%
  • ADDEX (CH)4.03 CHF79.9%

FLOP

  • MERCK KGAA (D)64.38 EUR-49.4%
  • HYBRIGENICS (F)1.77 EUR-27.5%
  • CHRONTECH PHARMA (S)0.07 SEK-22.2%

TOP

  • SANTHERA (CH)67.95 CHF3297.5%
  • GW PHARMACEUTICALS (UK)419.75 GBP642.9%
  • PAION (D)2.77 EUR319.7%

FLOP

  • CYTOS (CH)0.26 CHF-92.4%
  • EVOCUTIS (UK)0.21 GBP-91.8%
  • THROMBOGENICS (B)9.54 EUR-69.4%

No liability assumed, Date: 28.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...


Current issue

All issues

Product of the week

Products